Comparing the current results to its competitors, Senseonics Holdings Inc reported Revenue increase in the 1 quarter 2026 by 98.73 % year on year. The sales growth was above Senseonics Holdings Inc 's competitors' average revenue growth of 8.5 %, achieved in the same quarter.
Senseonics Holdings Inc , slower than the average decrease reported by the company's competitors of -14.13 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -14.13 %
Senseonics Holdings Inc 's Comment on Competition and Industry Peers
The continuous glucose monitoring (CGM) systems market is competitive, with key players including Dexcom, Medtronic, and Abbott. These companies hold FDA approval and CE Mark certifications, enabling them to market their CGM systems in the United States and the European Economic Area. Dexcom's G6 and G7 models and Abbott's Freestyle Libre 2 and 3 feature factory calibration, eliminating the need for user calibration. Dexcom was the first to receive the FDA interoperable CGM (iCGM) designation, with Abbott also obtaining this indication; Medtronic is expected to seek iCGM approval. The market also includes providers of self-monitoring of blood glucose (SMBG) systems such as Roche Diabetes Care (a division of Roche Diagnostics), Abbott, and Ascensia. Additional competition arises from companies developing new CGM technologies, including real-time intermittent sensing devices, low-cost transcutaneous CGM systems, fully implantable CGM devices, and non-invasive CGM systems. While the company cites its technology, expertise, and scientific resources as competitive strengths, many competitors possess greater financial resources and capabilities in research and development, manufacturing, clinical trials, regulatory approvals, and marketing.
Abbott Laboratories operates as a diversified healthcare company with a focus on developing and manufacturing a wide range of health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. Their business model emphasizes innovation and quality, aiming to address the diverse needs of patients and healthcare providers across various sectors globally. By leveraging their expertise and extensive portfolio, Abbott strives to enhance patient outcomes and improve the overall quality of life.
Endra Life Sciences Inc's business model focuses on developing and commercializing advanced imaging technologies and solutions for medical and industrial applications.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Sources:
Senseonics Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Senseonics Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
